On the stock market since 1994, it operates in the world of health and science. It has 19 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 52% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 18 buys and 3 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $140 — 466,567% above today’s price.
It pays out $0.60 per share each year — regular cash for whoever holds the stock.
A loss of $14.7M against $4.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.03. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, PRPH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PRPH is a small company that closed last year at a loss. The road back to profit runs through spending discipline.
Analysts’ average target sits above today’s price, yet the valuation grade (1/100) says the stock isn’t cheap.